Earnings Release Schedules, Corporate Updates, Quarterly Earnings Updates, and Regulatory Approvals - Analyst Notes on DCT Industrial, Zillow, E*TRADE Financial, Baxter International and Danaher

NEW YORK, April 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding DCT Industrial Trust Inc. (NYSE: DCT), Zillow, Inc. (NASDAQ: Z), E*TRADE Financial Corporation (NASDAQ: ETFC), Baxter International Inc. (NYSE: BAX) and Danaher Corporation (NYSE: DHR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1728-100free.

--
DCT Industrial Trust Inc. Analyst Notes
On April 2, 2014, DCT Industrial Trust (DCT Industrial) announced that it will release its financial results for Q1 2014 after the market closes on May 1, 2014 and will host a conference call the following day at 11 a.m. ET to discuss the performance. In the preceding quarter ended December 31, 2013, the Company had reported net income attributable to common stockholders of $13.9 million, or $0.04 per diluted share, compared with a net loss attributable to common stockholders of $0.8 million, or $0.00 per diluted share, in Q4 2012. For full-year 2014, the Company expects net income attributable to common stockholders to be between $0.06 and $0.09 per diluted share. The full analyst notes on DCT Industrial are available to download free of charge at:

http://www.analystsreview.com/1728-DCT-28Apr2014.pdf

--
Zillow, Inc. Analyst Notes
On April 7, 2014, Zillow, Inc. (Zillow) announced that Rich Barton, the Company's Co-founder and Executive Chairman, has been named as one of the 11 inaugural members of the Presidential Ambassadors for Global Entrepreneurship (PAGE) by Department of Commerce. According to the Company, Barton also participated in PAGE kick-off meetings with a number of officials, including U.S. Secretary of Commerce Penny Pritzker, U.S. Agency for International Development (USAID) Administrator Rajiv Shah, and other inaugural PAGE members. Commenting on the development, Barton said, "I am honored to be appointed to this esteemed group and look forward to working with the President, Secretaries Kerry and Pritzker, Administrator Shah and my fellow ambassadors to help support the rise of entrepreneurs and startup ecosystems globally." The full analyst notes on Zillow are available to download free of charge at:

http://www.analystsreview.com/1728-Z-28Apr2014.pdf

--
E*TRADE Financial Corporation Analyst Notes
On April 23, 2014, E*TRADE Financial Corporation (E*TRADE Financial) released its financial results for Q1 2014 and surpassed the analysts' estimates with nearly three-fold jump in net income at $97 million, or $0.33 per diluted share. On average, analysts polled by Bloomberg expected the Company to report an adjusted diluted EPS of $0.22. The net revenues of the Company also increased 13.1% YoY to $475 million. The Company ended the quarter with 3.1 million brokerage accounts, an increase of 72,000 from the prior quarter. Total customer assets at the end of Q1 2014 also increased to $269 billion from $261 billion at the end of Q4 2013. Commenting on the performance, CEO Paul Idzik said, "Overall positive investor sentiment elevated brokerage activity to its highest level in nearly five years, which aided our record net new brokerage assets and brokerage account retention." The full analyst notes on E*TRADE Financial are available to download free of charge at:

http://www.analystsreview.com/1728-ETFC-28Apr2014.pdf

--
Baxter International Inc. Analyst Notes
On April 23, 2014, Baxter International Inc. (Baxter) announced that the U.S. Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system. According to the Company, this new reconstitution system was developed to reduce the number of steps in the reconstitution process for hemophilia A patients in comparison to the earlier process with the BAXJECT II needle-less transfer device. Ludwig Hantson, Ph.D., President of Baxter BioScience, said, "ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment with fewer steps." The full analyst notes on Baxter International are available to download free of charge at:

http://www.analystsreview.com/1728-BAX-28Apr2014.pdf

--
Danaher Corporation Analyst Notes
On April 16, 2014, Danaher Corporation (Danaher) announced results for Q1 FY 2014 (period ended March 28, 2014). Net income during the quarter came in at $579.7 million, or $0.81 per diluted share, down from $691.9 million, or $0.98 per diluted share, in Q1 FY 2013. Danaher's sales during the quarter were $4.7 billion, representing an increase of 4.9% YoY. Analysts polled by Bloomberg estimated adjusted earnings per share of $0.80 on revenues of $4.7 billion. Looking ahead, Danaher expects Q2 2014 earnings to be in the range of $0.90 to $0.94 per share, while analysts at Bloomberg expected it to come at $0.96. The Company reaffirmed its full year GAAP 2014 diluted EPS guidance of $3.60 to $3.75. The full analyst notes on Danaher are available to download free of charge at:

http://www.analystsreview.com/1728-DHR-28Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review